A

rena Pharmaceuticals passed the first test of its drug development comeback strategy by delivering positive results from a mid-stage study targeting pulmonary arterial hypertension (PAH), a rare and debilitating disease caused by high blood pressure in the arteries that connect the heart to the lungs.

In the study of 61 PAH patients already on standard background therapy, Arena’s experimental drug ralinepag reduced pulmonary vascular pressure by 30 percent compared to a placebo. The difference was statistically significant, achieving the primary endpoint of the study. Pulmonary vascular pressure measures the pressure inside the arteries connecting the lungs with the heart.

This is a STAT Plus article and you can unlock it by subscribing to STAT Plus today. It's easy! Your first 30 days are free and if you don't enjoy your subscription you can cancel any time.
Already a subscriber? Log in here.

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Morning Rounds newsletter

Your daily dose of news in health and medicine.

X